52.3 F
Washington D.C.
Saturday, September 25, 2021
Advertisement

U.S. to pause Johnson & Johnson vaccine use over blood clot reports – National

Must Read


U.S. federal health agencies are recommending an immediate “pause” in the use of Johnson & Johnson’s single-dose COVID-19 vaccine after six U.S. recipients developed a rare disorder involving blood clots.

The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention said in a joint statement on Tuesday that the pause has been recommended “out of an abundance of caution”

Read more:
Johnson & Johnson vaccine under review in Europe after blood clot reports

The New York Times was first to report the suspension, citing officials briefed on the decision.

“Right now, these adverse events appear to be extremely rare,” the FDA wrote on Twitter. “Treatment of this specific type of blood clot is different from the treatment that might typically be administered.”

Story continues below advertisement

All the six recipients were women between the ages of 18 and 48. One woman died and a second woman in Nebraska has been hospitalized in critical condition, the NYT reported.

More than 6.8 million doses of the J&J vaccine have been administered in the U.S.

The CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. The FDA will then review that analysis as it also investigates these cases, it said in a statement.

Though this is a recommendation, experts say the U.S. administration is likely to follow it.

Story continues below advertisement

U.S. federal distribution channels, including mass vaccination sites, will pause the use of the J&J shot, and states and other providers are expected to follow.

Read more:
Johnson & Johnson says batch of COVID-19 vaccines failed quality check

A press conference will be held at 10 a.m. EDT where officials will provide further detail on the pause.

The company’s shares were down 3 per cent before the opening bell.

The move from the U.S. regulators comes less than a week after Europe’s drug regulator said it was reviewing rare blood clots in four people in the United States who received the shot.


Click to play video: 'Minister Anand says Johnson & Johnson COVID-19 vaccine on schedule for end of April'



Minister Anand says Johnson & Johnson COVID-19 vaccine on schedule for end of April


Minister Anand says Johnson & Johnson COVID-19 vaccine on schedule for end of April

Canada has also approved the one-shot Johnson and Johnson vaccine, however, deliveries to the country are not expected to begin until the end of April.

Story continues below advertisement

Canada also moved to change recommendations for use of the AstraZeneca vaccine after the reports of very rare blood clots in some recipients, although there have been no such reports in the country.

— with files from Reuters and the Associated Press



© 2021 Global News, a division of Corus Entertainment Inc.



- Advertisement -spot_img

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest News

- Advertisement -spot_img

More Articles Like This

- Advertisement -spot_img
Translate »